James Guest describes a recent clinical trial success using electrical stimulation of the cervical spinal cord, and also discusses best...

Angela Ruban describes how NeuroHagana is developing a treatment to lower blood glutamate levels that she believes would ideally be...

Brian Skorney gives his take on biotech and discusses Sarepta, Lexeo, Gilead, Mirum, Amgen, Vertex, Neurocrine, and Applied Therapeutics.

Paul Bradshaw explains how Inteligex's "ReStaRT Cells" are designed with a regional identity, and the rationale for engineering them to...

Mike Kelly explains the scientific rational for this peptide-based treatment, highlights its preclinical and phase 1 profile, and...

Laura Sepp-Lorenzino shares details of this news and offers her opinion of the significance of it, and provides an overview of Intellia's...

Brian Culley describes the need for an spinal cord injury focused investor conference and how the SCI Investor Symposium has grown over...

Paul Bolno highlights biomarker and safety data in Huntington's, the potential regulatory path ahead, and what to watch throughout the rest

Chris Hollowood gives his take on biotech, the UK, portfolio companies iOnctura, Yellowstone Biosciences, and Spur Therapeutics...

She describes how patients might benefit from UroGen's gel based technology that keeps chemotherapy locally in the bladder vs having...

David Domzalski discusses how Vyne is using this target that is traditionally thought of in oncology.

Tom Miller describes the rationale for the raise and what it will allow Iambic to do, how he believes the company's AI approach is unique

Yvonne Greenstreet shares her thoughts on key points of today's top-line, but as monotherapy and in combination, the potential market, and w

Luca Issi gives his take on the sector and discusses news regarding Moderna, Caribou, Ultragenyx, Biomarin, Alnylam, Lexeo, and Wave Life...

Michael McElhaugh describes data presented at EASL for the RNAi therapeutics imdusiran, explains the rationale for the PD-L1, and more.

Mike Ehlers describes how this $42M upfront and up to $1.8B in potential milestones deal is focused on neurological conditions, how RNA...

Cardiology expert Ethan Weiss describes the difference between ANGPTL4 and ANGPLT3, the rationale for lowering remnant cholesterol,...

Amy Brown will be covering biotech news and research in the London-Oxford-Cambridge triangle area for BiotechTV.

CEO Lisa Deschamps describes this now clinical program for frontotemporal dementia, and Aviado's broader platform for using gene...